Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

H. Henry, David; Costa, Luís; Goldwasser, François; Hirsh, Vera; Hungria, Vânia; Prausová, Jana; V. Scagliotti, Giorgio; Sleeboom, H.P.; Spencer, Andrew; Vadhan‐Raj, Saroj; von Moos, Roger; Willenbacher, Wolfgang; J. Woll, Penella; Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard

doi:10.1200/jco.2010.31.3304

Public

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Published in Journal of Clinical Oncology • Feb 23, 2011

Authors:

David H. Henry

Luís Costa

François Goldwasser

Abstract

PURPOSE: This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) ...

Subject

Medicine

Denosumab

Zoledronic acid

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!